The relation between venous and arterial thrombosis

Slides:



Advertisements
Similar presentations
1 Prediabetes Screening and Monitoring. 2 Prediabetes Epidemiologic evidence suggests that the complications of T2DM begin early in the progression from.
Advertisements

The Research Question Alka M. Kanaya, MD Associate Professor of Medicine, Epidemiology & Biostatistics UCSF October 3, 2011.
Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.
Special Diabetes Program for Indians Competitive Grant Program SPECIAL DIABETES PROGRAM FOR INDIANS Competitive Grant Program Clinical Goals for the Healthy.
Chapter 11 Diet and Health
Venous thromboembolism: how long to treat?
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
Healthy eating for middle-years Professor Tom Sanders Nutritional Sciences Division.
LIFEBLOOD THE Thrombosis CHARITY Venous thromboembolism – Treatment and secondary prevention Ulcus cruris Chronic PE PE DVT Post-thrombotic syndrome Death.
Effects of Low-Fat Dairy Consumption on Markers of Low- Grade Systemic Inflammation and Endothelial Function in Overweight and Obese Subjects: An Intervention.
Extended Anticoagulation in VTE Geoffrey Barnes, MD Cardiovascular and Vascular Medicine University of Michigan, USA 1 st Qatar Conference on Safe Anticoagulation.
Supervisor: Vs 余垣斌 Presenter: CR 周益聖. INTRODUCTION.
HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.
METABOLIC Syndrome: a Global Perspective
STUDY REGARDING THE LIFESTYLE AND EATING HABITS AS RISK FACTORS FOR HEART DISEASE, IN CORONARY PATIENTS FROM THE HEART DISEASE CLINIC II ADULTS UMF Tg-Mures.
DEFINING THE DURATION OF ANTICOAGULATION. HOW LONG TO TREAT A DVT?
Organizational criteria for Metabolic Syndrome National Cholesterol Education Program Adult Treatment Panel III World Health OrganizationAmerican Association.
Pulmonary Embolism Treatment in Cancer - Is It Different 34th Brazilian Thoracic Conference 6th ALAT Congress 5th Brazil-Portugal Congress Brazilia/DF.
Antiplatelet Therapy Use and the Risk of Venous Thromboembolic Events in the Double-Blind Raloxifene Use for the Heart (RUTH) Trial C. Duvernoy 1, A. Yeo.
Studying mortality trends: The IMPACT CHD Policy Model
Diabetes Centre Hippokration Hospital Athens, Greece B. KARAMANOS 2007 Report of he MGSD Nutrition Study B. Karamanos MD Associate Professor of Medicine.
Pai JK et al. N Engl J Med 2004; 351: Relative CHD risk by increasing baseline CRP plasma levels,* relative to CRP
1 INTIMA MEDIA THICKNESS AND ATHEROSCLEROSIS Michele CAZAUBON, MD, PhD American Hospital of Paris ( France)
Dr. I. Selvaraj Indian Railways Medical Service B.Sc., M.B.B.S., M.D.,D.P.H., D.I.H., PGCHFW ( NIHFW,New Delhi)., Life member of Indian Association of.
Insulin Resistance Progression to Diabetes. Hypertension: BP >140/90 Dyslipidemia: ◦TG >150 mg/dL (1.7 mmol.L) ◦HDL-C
Duration of Anticoagulation 5 Patients Categories 3. First Episode: 4. First Episode: 5.Recurrent DVT 2. First Episode: 1. First Episode: Transient risk.
Chapter 14 Patterns in Health and Disease: Epidemiology and Physiology EXERCISE PHYSIOLOGY Theory and Application to Fitness and Performance, 6th edition.
Metabolic Syndrome Endocrine Block 1 Lecture Dr. Usman Ghani.
Abstract The metabolic syndrome (MetS) has surpassed smoking as the number one cause of cardiovascular deaths in the US. However, it remains under diagnosed.
Nonalcoholic Fatty Liver Disease and Risk of Future Cardiovascular Events Among Type 2 Diabetic Patients Giovanni Targher, Lorenzo Bertolini, Felice Poli,
Yusra Mir, MD Zunairah Syed, MD Harjagjit Maan, MD
Chapter 11 Diet and Health
Copyright © 2015 by the American Osteopathic Association.
Endocrine Block 1 Lecture Dr. Usman Ghani
Clinical Professor in Palliative Medicine
Endocrine Block Dr. Usman Ghani
Waist-to-Hip Ratio is a Superior Predictor of Atherosclerosis Compared with Body Mass Index in a Population-Based Sample: Observations from the Dallas.
By Dr. Sumbul Fatma Clinical Chemistry Unit Department of Pathology
Insulin resistance, body mass index and venous thromboembolism
Hypertension Hanna K. Al-Makhamreh, MD FACC Interventional Cardiology.
Phenotype vs. Genotype: Defining Severe Familial Hypercholesterolemia
Endocrine Block 1 Lecture Dr. Usman Ghani
Cardiovascular Disease Risk in Patients with Rheumatic Diseases
ASSOCIATIONS OF METABOLIC SYNDROME COMPONENTS WITH CRITERIA FOR THE CLINICAL DIAGNOSIS OF THE METABOLIC SYNDROME AS PROPOSED BY THE NCEP-ATP III Metabolic.
Comparison of baseline characteristics in participants who subsequently had an incident cardiovascular event or new-onset diabetes in the Prospective.
HDL cholesterol and cardiovascular risk Epidemiological evidence
Lipids in Health and Disease
Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults Risks and Assessment NHLBI Obesity Education.
HDL cholesterol and cardiovascular risk
Prehypertension, Diabetes, and Cardiovascular Disease Risk in a Population-Based Sample by Ying Zhang, Elisa T. Lee, Richard B. Devereux, Jeunliang Yeh,
AIM-HIGH Niacin Plus Statin to Prevent Vascular Events
Hazard ratio (HR) for mortality for a 1-kg/m2 increase in body mass index (BMI) across the range of baseline BMI among patients with acute ischemic stroke.
Chapter 10 Diet and Health
Lipids in Health and Disease
Screening and Monitoring
Extended Treatment of VTE: Who is the Right Candidate?
ACC 2018 Orlando, Florida Interleukin-1b Inhibition with Canakinumab and Cardiovascular Event Reduction Among Patients with Moderate Chronic Kidney Disease.
Timothy A. Brighton, M. B. , B. S. , John W. Eikelboom, M. B. , B. S
Comparison of lipid profile and glycosylated hemoglobin levels among HIV-infected and non-HIV-infected individuals in Lesotho: a community-based cross-sectional.
Metabolic Syndrome (N=160) Non-Metabolic Syndrome (N=138) 107/53
Type 2 diabetes: Overlap of clinical conditions
Exercise and adult women’s health
Level of risk factor control in the overall sample and by gender
A Randomized Trial of Rosuvastatin in the Prevention
Lipids in Health and Disease
Chapter 7 LIPIDS IN HEALTH & DISEASE
Cardiovascular Disease in Women Module III: Risk Assessment Tool
Preventative Cardiology
Multivariable-adjusted HRs and 95% CIs for outcomes for waist circumference. Multivariable-adjusted HRs and 95% CIs for outcomes for waist circumference.
ACC 2018 Orlando, Florida Interleukin-1b Inhibition with Canakinumab and Cardiovascular Event Reduction Among Patients with Moderate Chronic Kidney Disease.
Presentation transcript:

The relation between venous and arterial thrombosis Walter Ageno Department of Clinical Medicine University of Insubria Varese - Italy

Asymptomatic atherosclerosis and deep vein thrombosis Atherosclerosis defined by ultrasound detected carotid plaques in patients with DVT and controls Atherosclerosis Idiopathic DVT 47% Secondary DVT 27.4% Controls 32% OR: 2.4 (1.4-4.0) (idiopathic vs secondary or controls) Prandoni et al, N Engl J Med 2003

Venous thromboembolism is associated with an increased risk of subsequent atherosclerosis

The long-term clinical course of PE Cardiovascular Events 0.40 Cardiovascular Events Idiopathic PE PE with transient RF 0.30 Cumulative Hazard 0.20 P=.005 0.10 0.00 6 12 18 24 30 36 42 48 Becattini et al., Eur Heart J 2005

Incidence of arterial cardiovascular events after venous thromboembolism: a systematic review and a meta-analysis IRR Unprovoked VTE vs Provoked VTE 1.86 (1.19-2.89) Controls 1.87 (1.32-2.65) Becattini et al JTH 2010

Atherosclerosis is not associated with an increased risk of subsequent venous thromboembolism

Cardiovascular risk factors and venous thromboembolism

Cardiovascular risk factors Obesity Hypertension Diabetes mellitus Dyslipidemia Smoking Metabolic syndrome

Obesity (BMI>30 Kg/m2) Hypertension Diabetes Triglycerides levels OR 2.33 (1.68, 3.24) Hypertension OR 1.51 (1.23, 1.85) Diabetes OR 1.41 (1.12, 1.77) Triglycerides levels WMD 17.48 (9.64, 28.33) HDL cholesterol levels WMD –2.86 (-4.34, -1.38)

Risk of VTE and Circumference of the Waist Arch. Int. Med. 1999; 159: 1886-90 50 60 70 80 90 100 54 65 75 Age (years) % of men without VTE after 26 years follow up Circumf. <100 cm Circumf. >100 cm

Anthropometric measures of obesity and risk of venous thromboembolism: the Tromso study Conclusions—Our findings indicate that WC is the preferable anthropometric measure of obesity to identify subjects at risk and to predict risk of VTE. Borch KH ATVB 2009

Metabolic Syndrome and inflammation Inflammatory adipokines: - TNF α - Leptin - Interleukin – 6 CRP Adiponectin

Metabolic Syndrome and risk of VTE: LITE study (12 years follow up) Idiopathic VTE events (n:195) Women Men (n=11,333) (n=8,863) Abdominal obesity 1.91 (1.23, 2.95) 2.42 (1.53, 3.81) High glucose 0.92 (0.57, 1.49) 1.06 (0.65, 1.72) High triglycerides 0.80 (0.49, 1.29) 0.79 (0.48, 1.32) Low HDL 0.59 (0.37-1.04) 1.57 (0.98-2.52) Elevated blood pressure 1.29 (0.85-1.98) 0.83 (0.52-1.33) Met Syn 0.76 (0.51-1.15) 1.59 (1.02-2.47) Steffen L et al JTH 2009

Risk of VTE in the Metabolic Syndrome: Tromso Study (11 years follow up) Age and gender adjusted HR (95 % CI) Metabolic syndrome 1.65 (1.22-2.23) Abdominal obesity 2.12 (1.59-2.83) Hypertriglyceridemia 1.26 (0.95-1.69) Low HDL cholesterol 1.07 (0.76-1.52) Hypertension 1.39 (0.98-1.97) Impaired glucose metabolism 1.51 (0.98-2.35) Borch K et al, JTH 2009

Common risk factors for arterial and venous thrombosis Advanced age Obesity Abdominal obesity Hormonal therapy Metabolic syndrome DIC HIT Antiphospholipid antibodies Hyperhomocysteinemia Cancer Myeloproliferative neoplasms PNH Heart failure Smoking Chronic kidney failure Nephrotic syndrome Inflammatory bowel disease

The effect of primary or secondary prevention strategies for cardiovascular disease in patients with venous thromboembolism

Fish, fruit, and vegetable intake and the risk of VTE Quintiles of daily nutrient intake Servings/d 1 2 3 4 5 p trend Fruit and vegetables Quintile ranges <2.5 2.5-3.5 3.5-4.5 4.5-5.8 >5.8 HR 1.0 0.73 0.57 0.47 0.59 0.03 95% CI n.s. .37-.90 .29-.77 .36-.99 Fish Quintile ranges <0.1 .1-.14 .15-.25 .25-.43 >0.43 HR 1.0 0.58 0.60 0.55 0.70 0.30 95% CI .37-.90 .39-.92 .35-.88 n.s. Red and processed meat Quintiles ranges <0.5 .5-.75 .75-1.0 1.0-1.5 >1.5 HR 1.0 1.24 1.21 1.09 2.01 0.02 95% CI n.s. n.s. n.s. 1.15-3.53 Steffen LM et al Circulation 2007

Alcohol consumption and the risk of VTE Alcohol consumers vs abstainers (2-4 glasses per day resulted in the largest beneficial effect) Overall OR 0.67 (0.58-0.77) Women OR 0.66 (0.53-0.84) Men OR 0.82 (0.63-1.07) PE only OR 0.56 (0.46-0.70) DVT only OR 0.74 (0.63-0.88) Fibrinogen levels were consistently decreased, FVII and vWF levels mildly decreased but not consistently Pomp ER et al Thromb Haemost 2008

Aspirin for the secondary prevention of VTE: WARFASA and ASPIRE pooled analysis Brighton T et al NEJM 2012

OR 0.81 (0.66-0.99)

Statin treatment reduces the risk of recurrent pulmonary embolism 3093 patients with a first episode of PE with a mean age of 61.3 ± 17.0 years. 737 patients (24%) had at least one prescription of statins during follow-up (median duration of statin therapy: 1557 days; 5-4055 days). During a median follow up of 1529 days (1-4155), 285 (9.2%) patients experienced a recurrent PE. Biere-Rafi S et al Eur Heart J 2012

Statin treatment reduces the risk of recurrent pulmonary embolism Treatment with statins reduced recurrent PE (HR 0.48, 95%CI 0.35-0.67) The protective effect was present both during and after stopping VKA treatment. A dose-response relationship was shown for both duration and potency Finally, statin treatment also reduced cardiovascular events and all-cause mortality. Biere-Rafi S et al Eur Heart J 2012

Conclusions Patients with (unprovoked) VTE are at increased risk of cardiovascular events Common risk factors may, at least in part, explain this association Effective treatment for the primary and secondary prevention of cardiovascular disease play a role also in the prevention of VTE